Abstract
Diagnosis of dyslipidemia currently relies on calculating LDL cholesterol concentration, a strategy with limitations that can lead to underestimation of the patient's lipid levels and, consequently, their cardiovascular risk. In this Viewpoint, James Stein and Patrick McBride discuss how alternative options for characterizing dyslipidemia, such as measurement of apoplipoprotein B-100 and non-HDL cholesterol, and determining LDL particle size by nuclear magnetic resonance spectroscopy, could have clinical application.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
